Ticker Details
Prelude Therapeutics Inc.
IPO Date:	September 25, 2020
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$340.09M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.52 | 4.64%
Avg Daily Range (30 D):	$0.26 | 5.44%
Avg Daily Range (90 D):	$0.18 | 5.41%

Institutional Daily Volume
Avg Daily Volume:	.25M
Avg Daily Volume (30 D):	.47M
Avg Daily Volume (90 D):	.36M

Trade Size
Avg Trade Size (Sh.):	128
Avg Trade Size (Sh.) (30 D):	100
Avg Trade Size (Sh.) (90 D):	115

Institutional Trades
Total Institutional Trades:	336
Avg Institutional Trade:	$1.96M
Avg Institutional Trade (30 D):	$.5M
Avg Institutional Trade (90 D):	$.81M
Avg Institutional Trade Volume:	.1M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.35M
Avg Closing Trade (30 D):	$.55M
Avg Closing Trade (90 D):	$.55M
Avg Closing Volume:	88.73K

News

Apr 20, 2026 @ 10:00 AM Prelude Therapeutics Presents Preclinical Data fro... Source: Na

Dec 6, 2025 @ 4:00 PM Prelude Therapeutics Presents Data at the 2025 ASH... Source: Prelude Therapeutics

Aug 14, 2025 @ 11:23 AM Prelude Cuts Q2 Losses and Costs 13% Source: Jesterai

Sep 13, 2024 @ 2:00 PM Prelude Therapeutics’ SMARCA2 Degrader PRT3... Source: Prelude Therapeutics Incorporated

Jun 3, 2024 @ 11:01 AM Prelude Therapeutics to Participate in Upcoming He... Source: Prelude Therapeutics, Inc.

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-1	$-.13	$-.2
Diluted EPS	$-1	$-.13	$-.2
Revenue	$16.72M	$4.58M	$5.64M
Gross Profit
Net Income / Loss	$-77.8M	$-10.39M	$-16.46M
Operating Income / Loss	$-84.14M	$-14.18M	$-17.35M
Cost of Revenue
Net Cash Flow	$-19.32M	$-13.5M	$-12.28M
PE Ratio